Cargando…
Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study
Because the optimal treatment for COVID-19 is still unknown, it is important to explore every potential way of improving the chances of survival for COVID-19 patients. The aim of the study was to analyze the effectiveness of convalescent plasma on COVID-19 patients. The study population consisted of...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795721/ https://www.ncbi.nlm.nih.gov/pubmed/33374333 http://dx.doi.org/10.3390/jcm10010028 |
_version_ | 1783634511612870656 |
---|---|
author | Moniuszko-Malinowska, Anna Czupryna, Piotr Zarębska-Michaluk, Dorota Tomasiewicz, Krzysztof Pancewicz, Sławomir Rorat, Marta Dworzańska, Anna Sikorska, Katarzyna Bolewska, Beata Lorenc, Beata Chciałowski, Andrzej Kozielewicz, Dorota Oczko-Grzesik, Barbara Szymanek-Pasternak, Anna Szetela, Bartosz Figlerowicz, Magdalena Rogalska, Magdalena Zaleska, Izabela Flisiak, Robert |
author_facet | Moniuszko-Malinowska, Anna Czupryna, Piotr Zarębska-Michaluk, Dorota Tomasiewicz, Krzysztof Pancewicz, Sławomir Rorat, Marta Dworzańska, Anna Sikorska, Katarzyna Bolewska, Beata Lorenc, Beata Chciałowski, Andrzej Kozielewicz, Dorota Oczko-Grzesik, Barbara Szymanek-Pasternak, Anna Szetela, Bartosz Figlerowicz, Magdalena Rogalska, Magdalena Zaleska, Izabela Flisiak, Robert |
author_sort | Moniuszko-Malinowska, Anna |
collection | PubMed |
description | Because the optimal treatment for COVID-19 is still unknown, it is important to explore every potential way of improving the chances of survival for COVID-19 patients. The aim of the study was to analyze the effectiveness of convalescent plasma on COVID-19 patients. The study population consisted of 78 patients diagnosed with COVID-19, selected from the SARSTer national database, who received convalescent plasma. The impact on clinical and laboratory parameters was assessed. A clinical improvement was observed in 62 (79%) patients, and 10 (13%) patients died from COVID-19. No side effects of the convalescent plasma treatment were observed. When plasma was administered earlier than 7 days from diagnosis, the total hospitalization time was shorter (p < 0.05). Plasma efficacy was inferior to remdesivir in endpoints such as the necessity and duration of oxygen therapy, the duration of hospitalization, and mortality rate, and inferior to other drugs in the case of the duration of hospitalization and the necessity of constant oxygen therapy, but comparable in most other measured endpoints. A comparison of a 30-day mortality rate in patients who received plasma and remdesivir (4/25, 16%) and who received only plasma (6/53, 11%) showed no significant difference. Convalescent plasma efficacy is inferior to remdesivir when treating COVID-19 patients but the addition of remdesivir to plasma does not improve the treatment effectiveness. In most endpoints, plasma was comparable to other treatment options. In our opinion, convalescent plasma may be used as a supportive treatment in COVID-19 patients because of the low frequency of adverse effects and availability, but must be given as early from the diagnosis as possible. |
format | Online Article Text |
id | pubmed-7795721 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77957212021-01-10 Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study Moniuszko-Malinowska, Anna Czupryna, Piotr Zarębska-Michaluk, Dorota Tomasiewicz, Krzysztof Pancewicz, Sławomir Rorat, Marta Dworzańska, Anna Sikorska, Katarzyna Bolewska, Beata Lorenc, Beata Chciałowski, Andrzej Kozielewicz, Dorota Oczko-Grzesik, Barbara Szymanek-Pasternak, Anna Szetela, Bartosz Figlerowicz, Magdalena Rogalska, Magdalena Zaleska, Izabela Flisiak, Robert J Clin Med Article Because the optimal treatment for COVID-19 is still unknown, it is important to explore every potential way of improving the chances of survival for COVID-19 patients. The aim of the study was to analyze the effectiveness of convalescent plasma on COVID-19 patients. The study population consisted of 78 patients diagnosed with COVID-19, selected from the SARSTer national database, who received convalescent plasma. The impact on clinical and laboratory parameters was assessed. A clinical improvement was observed in 62 (79%) patients, and 10 (13%) patients died from COVID-19. No side effects of the convalescent plasma treatment were observed. When plasma was administered earlier than 7 days from diagnosis, the total hospitalization time was shorter (p < 0.05). Plasma efficacy was inferior to remdesivir in endpoints such as the necessity and duration of oxygen therapy, the duration of hospitalization, and mortality rate, and inferior to other drugs in the case of the duration of hospitalization and the necessity of constant oxygen therapy, but comparable in most other measured endpoints. A comparison of a 30-day mortality rate in patients who received plasma and remdesivir (4/25, 16%) and who received only plasma (6/53, 11%) showed no significant difference. Convalescent plasma efficacy is inferior to remdesivir when treating COVID-19 patients but the addition of remdesivir to plasma does not improve the treatment effectiveness. In most endpoints, plasma was comparable to other treatment options. In our opinion, convalescent plasma may be used as a supportive treatment in COVID-19 patients because of the low frequency of adverse effects and availability, but must be given as early from the diagnosis as possible. MDPI 2020-12-24 /pmc/articles/PMC7795721/ /pubmed/33374333 http://dx.doi.org/10.3390/jcm10010028 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Moniuszko-Malinowska, Anna Czupryna, Piotr Zarębska-Michaluk, Dorota Tomasiewicz, Krzysztof Pancewicz, Sławomir Rorat, Marta Dworzańska, Anna Sikorska, Katarzyna Bolewska, Beata Lorenc, Beata Chciałowski, Andrzej Kozielewicz, Dorota Oczko-Grzesik, Barbara Szymanek-Pasternak, Anna Szetela, Bartosz Figlerowicz, Magdalena Rogalska, Magdalena Zaleska, Izabela Flisiak, Robert Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study |
title | Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study |
title_full | Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study |
title_fullStr | Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study |
title_full_unstemmed | Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study |
title_short | Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study |
title_sort | convalescent plasma transfusion for the treatment of covid-19—experience from poland: a multicenter study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795721/ https://www.ncbi.nlm.nih.gov/pubmed/33374333 http://dx.doi.org/10.3390/jcm10010028 |
work_keys_str_mv | AT moniuszkomalinowskaanna convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy AT czuprynapiotr convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy AT zarebskamichalukdorota convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy AT tomasiewiczkrzysztof convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy AT pancewiczsławomir convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy AT roratmarta convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy AT dworzanskaanna convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy AT sikorskakatarzyna convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy AT bolewskabeata convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy AT lorencbeata convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy AT chciałowskiandrzej convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy AT kozielewiczdorota convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy AT oczkogrzesikbarbara convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy AT szymanekpasternakanna convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy AT szetelabartosz convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy AT figlerowiczmagdalena convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy AT rogalskamagdalena convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy AT zaleskaizabela convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy AT flisiakrobert convalescentplasmatransfusionforthetreatmentofcovid19experiencefrompolandamulticenterstudy |